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important in guiding safe and rational adoption and use of
this technology in young patients. In June 2015, 24 inter-
national leaders in pediatric radiation oncology, pediatric
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Fig. 1. Participants’ responses to the question: “What is
the treatment of choice for the following pediatric tumors?”
Participants could answer “proton therapy,” “photon ther-
apy,” or “both, depending on circumstances.” Eighteen of
24 conference attendees participated in the survey.
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children with proton therapy. To encompass the spectrum
of current opinion, participants represented a wide
cross-section of public and private health care settings,
including institutions with access and those without access
to proton therapy. The meeting had 3 predefined aims: (1)
To better define the role of proton therapy in the manage-
ment of pediatric cancers; (2) to reach a consensus on the
clinical scenarios for which proton therapy provides the
most benefit in pediatric cancers; and (3) to prioritize the
innovation and development necessary to advance the
subspecialty. These aims were accomplished via interactive
presentations, anonymous surveys, facilitated dialogue,
group breakout sessions, and dosimetry plan comparisons.
Early in the meeting, full consensus was established on
fundamental aspects of pediatric radiation oncology. Using
existing technology, radiation therapy is very effective in
curing many pediatric tumors. However, participants uni-
formly agreed that delivery of radiation in pediatric patients
requires extra caution owing to the radiosensitive nature of
developing tissue, which has a low dose threshold for late
effects, and the long natural life expectancy of survivors.
The intent of pediatric radiation oncologists is consistent:
deliver as low a dose of radiation to as small a volume
necessary to cure the child. Although this paradigm is not
necessarily unique to children, pediatric radiation oncolo-
gists place a heightened emphasis on late effects. With
modern imaging and radiation therapy techniques, there are
many diverse paths that converge at this goal of reducing
radiation exposure to healthy tissue; participants concurred
that proton therapy represented but one avenue of
advancement toward this end.
Indications for Proton Therapy in Pediatrics
Common agreement was identified on broad topics
related to proton therapy indications. All participants
considered “access to a proton therapy system a
complement to my pediatric program.” The majority of
participants (58%) thought that most (50%-90%) of the
pediatric tumors requiring radiation should be treated
with proton therapy. However, no participant thought that
proton therapy should be systematically substituted for
photon radiation in every pediatric tumor, and 10% of
participants believed that less than 25% of pediatric
tumors should be treated with proton therapy. Participants
approached this question from the perspective of their
local, current health care environment in terms of
accessibility and cost of proton therapy.
Although this difference accounts for some of the
diversity in viewpoint, the main source of heterogeneity
was attributed to mixed opinions related to tumor type
and site, which is a surrogate for radiation dose and
sensitive normal tissues adjacent to the malignant target.
Many participants felt that disease-specific indications are
often vague and an oversimplification. Although generalrecommendations for specific disease sites can be made by
consensus, physicians and payers must veer from rigid
guidelines to address individual patient and disease
characteristics (such as age, comorbidities, anatomy, tumor
location, and tumor distance from critical structures). When
the group was presented with various clinical scenarios and
asked, “What is the treatment of choice for the following
pediatric tumors?,” clear trends emerged (Fig. 1).
Participants could answer “proton therapy,” “photon
therapy,” or “both, depending on circumstances.” The group
felt that proton therapy was a preferred indication for the
majority of pediatric central nervous system tumors, as well
as skull base tumors and retinoblastoma.
The exception was high-grade glioma of the brain and
brainstem, for which participants favored photon therapy
owing to the low cure rate and subsequent improbability a
child survives long-term to derive the relative reduction in
late complications. As a corollary, these tumors are highly
infiltrative and often recur in areas of the brain just beyond
the initially defined volume. The precision of proton
therapy in this setting may undermine its applicability. The
group also indicated that photon therapy was generally
appropriate for Wilms tumor, where the dosimetric
precision of proton therapy is unnecessary given the low
dose and broad targets encompassing the entire abdomen or
lungs. There was a diversity of opinion on Hodgkin
lymphoma and neuroblastoma, common midline tumors
that are curable with a lower radiation dose. There were
also mixed opinions on rhabdomyosarcoma and Ewing
sarcoma, for which the relative value of proton therapy
depends on the anatomic tumor site.
To further advance the discussion regarding disease-
specific indications, comparison plans were reviewed for
ependymoma, craniopharyngioma, medulloblastoma, and
rhabdomyosarcoma. Each respective plan was generated
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predominantly photon institution and a pediatric radiation
oncologist from a predominantly proton institution. The
specific photon and proton technique (such as intensity
modulated radiation therapy, volumetric arc therapy,
tomotherapy, double-scattering proton delivery, or
pencil-beam proton delivery) was not constrained.
Instead, experienced pediatric radiation oncologists and
their staff selected their best available option to simulate
“real-world” circumstances, which in turn introduced
variability and bias owing to different planning goals and
priorities.
Across all plan comparisons, the integral dose was lower
for proton therapy, although the magnitude of relevance
was debated. For posterior fossa ependymoma, the most
clinically meaningful difference was a lower dose to the
cochlea, temporal lobes, and hypothalamicepituitary axis
with the proton plan (Fig. 2). For the craniopharyngioma,
the most clinically relevant difference observed was the
reduced lowemoderate dose to the supratentorial brain
(Fig. 3). The impact of this difference on cognitive
development is theorized and age-dependent. For the
medulloblastoma case, proton therapy reduced the dose to
the lung, heart, face, abdomen, and pelvis but delivered a
higher dose to the scalp and paraspinal soft tissue.
There were mixed differences with regard to brain
exposure, with the photon plan delivering a higher dose to
the frontal and temporal lobes, whereas the proton plan
delivered a higher dose to the medial parietal and occipital
lobes (Fig. 4). For the parameningeal rhabdomyosarcoma
case, proton therapy delivered a lower dose to the cochlea,
oral cavity, face, and infratentorial brain but a higher dose
to the frontal lobe and larynx (Fig. 5). Although valuable
for discussion, this dosimetric exercise was not intended toFig. 2. Posterior fossa ependymoma photon (IMRT, top) anbe exhaustive nor reach a definitive conclusion, and the
details of each plan comparison are beyond the scope of
this report. Instead, readers are referred to more rigorous
and standardized dosimetric comparisons of proton and
photon therapy for ependymoma, craniopharyngioma,
medulloblastoma, and rhabdomyosarcoma published in
high-impact journals over the last decade, including articles
by Macdonald et al (3), Boehling et al (4), Lee et al (5), and
Ladra et al (6).Magnitude of Benefit and Patient
Prioritization
The conference participants spent considerable time
exploring the magnitude of benefit and pediatric patient
prioritization. Compared with other current pediatric
indications, the group felt that the relative amount of
benefit for total body irradiation, whole-abdomen
irradiation, whole-lung irradiation, and whole-brain
irradiation was questionable. In fact, the value of proton
delivery may be so low under these conditions that some
participants asked whether it was outweighed by the
uncertainties surrounding aspects of particle therapy dose
deposition. For example, are the benefits of “cardiac- and
breast-sparing” whole-lung radiation outweighed by the
technical uncertainty of proton delivery? Are the benefits
of “lens-sparing” whole-brain radiation outweighed by
the ill-defined, end-of-range radiobiologic effect on the
optic nerves and retina when delivered via a posterior
beam?
In cases with a consensus view of probable benefit,
group members posed questions of prioritization. In a child
with metastatic incurable cancer, do we use protons tod proton (IMPT, bottom) comparison plans in 3 planes.
Fig. 3. Craniopharyngioma photon (IMRT, top) and proton (bottom) comparison plans in 3 planes.
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tons be applied to reduce a hypothetical risk of unilateral,
high-frequency hearing loss from 7% to 5%? In this
context, it is important to recognize that in many cases,
pediatric radiation oncologists often do not possess modelsFig. 4. Medulloblastoma proton and photon comparison plan
tomotherapy. Right: A dose subtraction image to highlight diffeto accurately quantify side-effect risks and therefore must
be cautious not to overstate precision when claiming the
comparative estimates of benefit. Even when data are
available to accurately characterize risk, decisions of pa-
tient prioritization are linked to the supply of availables. Left: Proton pencil beam (PBS) plan. Middle: Photon
rences between the 2 modalities.
Fig. 5. Parameningeal rhabdomyosarcoma proton and photon comparison plans. Left: Proton pencil beam (PBS) plan.
Middle: Photon tomotherapy. Right: A dose subtraction image to highlight differences between the 2 modalities.
Volume 96  Number 2  2016 Stockholm pediatric proton therapy conference 391proton treatment slots, which in turn depend on health care
resources and cultural expectations. Finally, given the
limited distribution of proton centers worldwide, we should
be cognizant of the financial and emotional burden placed
on families that must relocate to a distant treatment facility.
When families feel compelled to provide the “very best” for
their children, the dialogue needs to encompass all aspects
of medical care, including psychosocial elements.
The group reached a consensus on long-term goals to
aid in patient prioritization. With respect to side-effect
reduction, pediatric doseeeffect models need to be
developed and refined across all radiation modalities. In
the ideal setting, accurate modeling will permit detailed,
patient-specific “virtual trials,” which can then be placed
into the context of local health care environments. With
respect to improving tumor control rates, the use of proton
therapy to increase tumor dose (and possibly cure rates) is
promising but should be explored within formal clinical
trials. Until these long-term goals are achieved, the group
settled on the broad position that the best proton candidate
is a young child with a curable tumor requiring the de-
livery of moderate to high focal radiation dose in prox-
imity to critical tissue. Though lacking objective
quantification, this approach of patient prioritization will
optimize both the magnitude of risk reduction and the
duration of benefit.Barriers to the Use of Proton Radiation
Therapy
Beyond these concerns, conference participants discussed
existing barriers to proton therapy. Participants felt strongly
that more research was needed on the radiobiology of
protons in children, specifically investigations involving the
end of range radiobiologic and physical dose uncertainty.
One-third of the group felt that radiobiologic uncertainty
represented a “significant obstacle for broad adoption of
proton therapy.” In addition, the group largely agreed that
ongoing lack of pediatric treatment capacity worldwide,
particularly at proton centers committed to research and
those with pediatric expertise, represented an important
barrier. Finally, the participants vocalized concerns about
persistent referral barriers even when there was an
unambiguous medical indication for proton therapy. This
apprehension branched into diverse themes.
For example, one participant shared the perspective,
“These doctors bought a proton machine and suddenly
think they are pediatric radiation oncologists.” In reality,
the complexity of delivering quality pediatric care
extends far beyond radiation modality. It commonly
involves unique aspects of anesthesia/immobilization,
setup imaging, multiagent concurrent chemotherapy, family
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resources for participation in cooperative protocols.
Another type of referral barrier was characterized by the
statement, “It is too expensive for my state/country to refer
every child for proton therapy. We have higher health care
priorities and less resources.” In fact, this is a reality for
most of the world’s population. What happens when one’s
role as an individual patient fiduciary conflicts with one’s
role as societal fiduciary? There is no easy answer to such a
question; it requires deliberate ethical introspection and
pragmatism. A third theme identified as a referral barrier is
reflected in sentiments such as, “If I refer this child for
proton therapy, I will not meet my salary revenue goals,” or
“I have been treating children with radiation for decades
and I am very skilled at what I do. There is no need for
me to refer a patient elsewhere.” Issues of personal
reimbursement and professional ego are uncomfortable
topics for each of us to confront.
Perhaps equally revealing were issues that conference
participants did not view as significant barriers to broad
proton therapy implementation in children. One example is
the issue of neutron contamination generated by proton
scatter (7, 8). Generally speaking, the attendees did not feel
this out-of-field exposure represented an undue risk of radi-
ation carcinogenesis when considered in light of the reduced
dose along the beam path afforded by proton therapy.
Nevertheless, participants agreed that newer techniques of
pencil beam delivery, which further reduce neutron scatter,
will provide extra reassurance. In addition, participants did
not consider randomized studies or data from a “model-based
approach” to patient selection as mandatory before broad
adoption of pediatric proton therapy. Although each holds
value, the subsequent delay in proton therapy implementa-
tion is not justified given the current level of evidence
available for most common pediatric tumors. Furthermore,
the feasibility of such trials is highly questionable given the
current accessibility of proton therapy and biases in patient
selection related to patient and physician preference.
The conference concluded with a consensus on the most
desirable areas for advancement within pediatric proton
therapy delivery. The overwhelming highest priority was
reduction in cost of proton therapy systems, specifically the
enormous capital investment required to purchase hardware.
Although protons may result in long-term cost savings when
utilized in children (9), short-term economic viability cannot
be ignored. Given their complexity, treating pediatric
cancers with proton therapy isdat bestda cost-neutral
activity over the short term, and efforts to recover the high
cost of proton therapy equipment result in pressure to treat
more profitable diseases in adults (10).
Another high-priority concern was the need for a
formalized national or international registry of children
treated with proton therapy. Such an undertaking would be
expensive and complicated but may represent the quickest
way to gather data on disease control and empirically
refine our models of pediatric normal-tissue dose effect.
Other important needs included the development of safe,volumetric image guidance (such as low-dose cone-beam
computed tomography with a collimated, variable field of
view). Most proton facilities currently rely on less
advanced orthogonal kilovoltage image guidance.
Additionally, participants desire treatment rooms that
comfortably accommodate anesthesia units and are equip-
ped with age-appropriate entertainment/distraction devices.
The conference was successful in that a diverse group of
international leaders identified common themes to shape
global discussion around the use of proton therapy in the
treatment of children with cancer. The broad consensus was
that the technology of proton therapy represents an
incremental and nonexclusive advancement in the field of
pediatric oncology, consistent with long-standing goals of
the specialty. Where available, it has an accepted role in
young children with curable tumors who require moderate
to high radiation doses. Yet important questions remain
surrounding the magnitude of benefit, patient prioritization,
and radiobiology. With the hope of moving the technology
forward in a way that best serves our pediatric patients,
the group identified specific technological and research
initiatives that require attention. As more evidence is
developed and more pediatric patients are treated
worldwide, a similar meeting should reconvene to provide
an updated perspective.References
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